“The analysis reveals a cohesive outlook: GLP-1 receptor agonists and dual GLP-1/GIP therapies will see continued rapid adoption for obesity and type 2 diabetes, with an expanding off-label cosmetic use among affluent consumers. Benefits in weight loss and glycemic control are clear, but emerging gastrointestinal side effects, nutritional deficiencies, adherence barriers, and long-term safety signals elevate the overall risk posture to moderate. No substantive divergences exist among the pillars; all align on the balance between high therapeutic value and the need for vigilant risk management.”